Pro Medicus (ASX: PME) Falls Despite A$40m in US Renewals: Is This a Buying Opportunity?

Pro Medicus Dips Despite Strong Renewals

Pro Medicus (ASX: PME) slipped around 1% on Monday despite announcing approximately A$40m in US contract renewals, including an expanded deal with MedStar Health and a third renewal from imaging group Zwanger-Pesiri at higher per-transaction fees. The pullback has nothing to do with the business itself. It is a macro story, with broader market weakness dragging down high-multiple growth stocks across the board. For investors watching PME, the more interesting question is what these renewals actually reveal about the underlying business and whether a market-driven dip like this is worth acting on.

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

What Recent Renewals Actually Signal About Pro Medicus

The MedStar renewal carries particular significance because MedStar was Pro Medicus’s first fully cloud-deployed customer. The fact that it is not just renewing but expanding into cardiology imaging is important. It suggests the Visage platform deepens its footprint within hospital networks over time rather than staying confined to its original use case in radiology. That is exactly the kind of expansion dynamic that makes a software business genuinely valuable.

Zwanger-Pesiri’s third renewal is equally telling. A customer renewing once could be inertia. Renewing three times, at progressively higher fees, is something different. It tells us the switching costs are real and the value delivered is growing. We believe this 100% renewal track record is one of the strongest signals Pro Medicus can send to the market, and the recent announcement reinforces it.

The Bull Case for Pro Medicus Is Still Intact

What makes Pro Medicus compelling as a long-term holding is the size of the opportunity still ahead of it. The company has penetrated roughly 10% of the US radiology market, yet the addressable opportunity remains vast, with the majority of US hospitals still running legacy imaging systems. The addressable market is large, and PME has barely scratched the surface.

Forward contracted revenue now exceeds A$1bn across its pipeline, providing strong near-term earnings visibility. The cardiology module expansion also opens a new market beyond radiology altogether, which could meaningfully extend PME’s growth runway over the coming decade. In our view, the fundamental story here is one of the most consistent on the ASX.

The Investors’ Takeaway

The challenge with Pro Medicus is not the quality of the business. It is the valuation. The stock currently trades at around 80 to 90 times forward earnings, which means the market is already pricing in years of near-perfect execution. At that multiple, there is very little room for error. Any renewal stumble, earnings miss, or guidance trim would likely be punished far more severely than the recent 1% dip.

For existing shareholders, we believe this remains a hold. The business is performing exactly as expected, the US expansion is progressing, and the moat is deepening with every renewal cycle. For new investors looking to build a position, however, the current entry point is difficult to justify on valuation alone. The better strategy, in our view, is to wait for a broader market pullback to improve the risk-reward profile before initiating a position. PME is the kind of stock worth owning at the right price, and today is probably not that price.